Dystrophin immunogenicity and requirement in myogenic cells: Paradigm shift in gene therapy for DMD
Open Access
- 24 November 2022
- journal article
- editorial
- Published by Wiley in Clinical and Translational Medicine
- Vol. 12 (11) , e1122
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Loss of full-length dystrophin expression results in major cell-autonomous abnormalities in proliferating myoblastseLife, 2022
- Morpholino‐induced exon skipping stimulates cell‐mediated and humoral responses to dystrophin in mdx miceThe Journal of Pathology, 2019
- Co-delivery of indoleamine 2,3-dioxygenase prevents loss of expression of an antigenic transgene in dystrophic mouse musclesGene Therapy, 2016
- Role of dystroglycan in limiting contraction-induced injury to the sarcomeric cytoskeleton of mature skeletal muscleProceedings of the National Academy of Sciences, 2016
- Dystrophin expression in muscle stem cells regulates their polarity and asymmetric divisionNature Medicine, 2015
- Jagged 1 Rescues the Duchenne Muscular Dystrophy PhenotypeCell, 2015
- Neonatal Systemic AAV Induces Tolerance to CNS Gene Therapy in MPS I Dogs and Nonhuman PrimatesMolecular Therapy, 2015
- Dystrophin is a tumor suppressor in human cancers with myogenic programsNature Genetics, 2014
- Dystrophin Immunity in Duchenne's Muscular DystrophyNew England Journal of Medicine, 2010
- RNAi-mediated knockdown of dystrophin expression in adult mice does not lead to overt muscular dystrophy pathologyHuman Molecular Genetics, 2008